EP1155038A1 - Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique - Google Patents

Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique

Info

Publication number
EP1155038A1
EP1155038A1 EP00910690A EP00910690A EP1155038A1 EP 1155038 A1 EP1155038 A1 EP 1155038A1 EP 00910690 A EP00910690 A EP 00910690A EP 00910690 A EP00910690 A EP 00910690A EP 1155038 A1 EP1155038 A1 EP 1155038A1
Authority
EP
European Patent Office
Prior art keywords
peptide
ige
mimotope
amino acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00910690A
Other languages
German (de)
English (en)
Inventor
Martin Corporate Intellectual Property FRIEDE
Sean Peptide Therapeutics Limited MASON
William Gordon Peptide Therapeutics Ltd. TURNELL
Marcelle P. SmithKline Beecham VAN MECHELEN
Carlota Smithkline Beecham VINALS Y DE BASSOLS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Sanofi Pasteur Holding Ltd
Original Assignee
SmithKline Beecham Biologicals SA
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by SmithKline Beecham Biologicals SA, Peptide Therapeutics Ltd filed Critical SmithKline Beecham Biologicals SA
Publication of EP1155038A1 publication Critical patent/EP1155038A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Definitions

  • the connection from strand a to strand b is labelled as the A-B loop, and so on.
  • the A-B and d-e loops belong topologically to the four-stranded sheet, and loop 1 g to the three-stranded sheet.
  • the interface between the pair of opposing sheets provides the hydrophobic interior of the globular domain. This water-inaccessible, mainly hydrophobic core results from the close packing of residue side-chains that face each other from opposing ⁇ -sheets.
  • the peptides may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail.
  • the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide.
  • modified peptides, or mimotopes could be a wholly or partly non-peptide mimotope wherein the constituent residues are not necessarily confined to the 20 naturally occurring amino acids.
  • these may be cyclised by techniques known in the art to constrain the peptide into a conformation that closely resembles its shape when the peptide sequence is in the context of the whole IgE molecule.
  • a preferred method of cyclising a peptide comprises the addition of a pair of cysteine residues to allow the formation of a disulphide bridge.
  • the peptides (as identified in tables 4 or 5, or derivatives or mimotopes thereof) is dissolved at 4 mg/ml in 0.1 M acetic acid to avoid di-sulfure bond formation.
  • a molar ratio of between 2 to 20 peptides per 1 activated Protein D is used for the coupling.
  • the peptide solution is slowly added to the protein and the mixture is incubated 1 h at 25°C.
  • the pH is kept at a value of 6.6 during the coupling phase.
  • a quenching step is performed by addition of cysteine (0.1 mg cysteine per mg of activated PD dissolved at 4 mg/ml in acetic acid 0.1 M), 30 minutes at 25°C and a pH of 6.5.
  • Two dialysis against NaCl 150 mM Tween 80 0.1 % are performed to remove the excess of cysteine or peptide.
  • P14 monoclonal antibodies were tested on basophils taken from four different allergic patients (A patients were allergic to dust mite antigen, G patients were allergic to grass pollen).
  • PT11 PTmAbOOl 1
  • All of the three P14 monoclonal antibodies 23, 31, and 33 were potent in inhibiting histamine release from allergic basophils (See FIG. 7).

Abstract

La présente invention concerne de nouveaux médicaments destinés au traitement, à la prévention ou à l'atténuation des allergies. Ces nouveaux médicaments sont notamment des peptides isolés comprenant des épitopes ou des mimotopes des régions exposées en surface du domaine Cε3 ou Cε4 des IgE. Les inventeurs ont découvert que ces nouvelles régions peuvent servir de cible à l'immunoprophylaxie ou à l'immunothérapie, active ou passive. L'invention concerne également des procédés de préparation de médicaments, des compositions pharmaceutiques les contenant et leur utilisation en médecine. L'un des aspects de la présente invention couvre des ligands, notamment des anticorps monoclonaux, qui sont capables de lier les régions exposées en surface des IgE selon la présente invention, et leur utilisation en médecine et en immunoprophylaxie ou en immunothérapie passive.
EP00910690A 1999-02-25 2000-02-22 Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique Withdrawn EP1155038A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GB9904408 1999-02-25
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GB9917144 1999-07-21
GB9918606 1999-08-07
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GB9918601 1999-08-07
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GB9918599 1999-08-07
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GB9918604 1999-08-07
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GB9918598 1999-08-07
GB9925618 1999-10-29
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine
PCT/EP2000/001456 WO2000050461A1 (fr) 1999-02-25 2000-02-22 Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique

Publications (1)

Publication Number Publication Date
EP1155038A1 true EP1155038A1 (fr) 2001-11-21

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00910690A Withdrawn EP1155038A1 (fr) 1999-02-25 2000-02-22 Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique

Country Status (18)

Country Link
EP (1) EP1155038A1 (fr)
JP (1) JP2002537403A (fr)
KR (1) KR20020007314A (fr)
CN (1) CN1520423A (fr)
AR (1) AR029619A1 (fr)
AU (1) AU3281100A (fr)
CA (1) CA2363641A1 (fr)
CO (1) CO5231139A1 (fr)
CZ (1) CZ20013081A3 (fr)
HK (1) HK1043134A1 (fr)
HU (1) HUP0105490A3 (fr)
IL (1) IL145025A0 (fr)
MX (1) MXPA01008612A (fr)
NO (1) NO20014131L (fr)
NZ (1) NZ513680A (fr)
PL (1) PL350992A1 (fr)
TR (1) TR200102493T2 (fr)
WO (1) WO2000050461A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (fr) * 1999-12-21 2001-06-28 Acambis Research Limited Technologie de liaison reversible pour conjugaison controlee
CA2407897A1 (fr) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Jeu ordonne d'antigenes moleculaires
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CA2489410C (fr) 2002-07-17 2015-01-13 Cytos Biotechnology Ag Reseaux d'antigenes moleculaires
KR20120041739A (ko) 2002-07-18 2012-05-02 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004085635A1 (fr) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Conjugues de particules d'aspect viral d'analogues du peptide melan-a
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP5389442B2 (ja) 2005-09-29 2014-01-15 メディミューン，エルエルシー 膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用
EP1973608A1 (fr) 2005-12-14 2008-10-01 Cytos Biotechnology AG Particules emballees avec des acides nucleiques immunostimulateurs pour le traitement de l hypersensibilite
DK2032592T3 (da) 2006-06-12 2013-09-02 Cytos Biotechnology Ag Fremgangsmåder til pakning af oligonukleotider til virus-lignende partikler af rna-bakteriofager
AU2009325950B2 (en) * 2008-12-09 2013-03-07 Pfizer Vaccines Llc IgE CH3 peptide vaccine
CA2800774A1 (fr) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Vaccin peptidique ige ch3
US9657071B2 (en) * 2012-06-18 2017-05-23 Nippon Zenyaku Kogyo Co., Ltd. IgE peptide vaccine
WO2019194656A1 (fr) * 2018-04-06 2019-10-10 (주)에스엘에스바이오 Nouvel épitope de l'immunoglobuline e, anticorps se liant à celui-ci, et kit d'analyse de l'immunoglobuline e dans un échantillon contenant celle-ci

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (ja) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有するペプチド
DE69233716T2 (de) * 1991-08-14 2008-10-30 Genentech Inc., San Francisco Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
ATE230417T1 (de) * 1996-03-01 2003-01-15 Novartis Erfind Verwalt Gmbh Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
AU6532498A (en) * 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0050461A1 *

Also Published As

Publication number Publication date
HK1043134A1 (zh) 2002-09-06
AR029619A1 (es) 2003-07-10
MXPA01008612A (es) 2003-06-24
NZ513680A (en) 2001-09-28
PL350992A1 (en) 2003-02-24
JP2002537403A (ja) 2002-11-05
HUP0105490A3 (en) 2002-05-28
NO20014131D0 (no) 2001-08-24
CZ20013081A3 (cs) 2002-02-13
NO20014131L (no) 2001-10-02
IL145025A0 (en) 2002-06-30
CN1520423A (zh) 2004-08-11
CA2363641A1 (fr) 2000-08-31
WO2000050461A1 (fr) 2000-08-31
TR200102493T2 (tr) 2002-02-21
KR20020007314A (ko) 2002-01-26
CO5231139A1 (es) 2002-12-27
AU3281100A (en) 2000-09-14
HUP0105490A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
WO2000050461A1 (fr) Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
JP4031201B2 (ja) アレルギー治療用免疫原としてのペプチド組成物
JP3421970B2 (ja) ペプチド免疫原
EP1155037A1 (fr) Epitopes ou mimotopes derives du domaine c-epsilon-2 de l'immoglobuline e, leurs antagonistes et leurs applications therapeutiques
US20040030106A1 (en) Novel compounds and process
WO2003092714A2 (fr) Vaccin
US20040115220A1 (en) Vaccine
US20050152892A1 (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutics uses
US20030170229A1 (en) Vaccine
US20050214285A1 (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
ZA200107016B (en) Epitopes or mimotopes derived from the C-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
MXPA00011938A (en) Peptide composition as immunogen for the treatment of allergy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20010910

17Q First examination report despatched

Effective date: 20040706

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051116

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1043134

Country of ref document: HK